Diabetes technology & therapeuticsSep 4, 2026

Additional Treatments for People with Type 1 Diabetes Using Automated Insulin Pumps

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 5, 2026

Abstract

In overweight and obese patients with type 1 diabetes treated with Automated Insulin Delivery, the addition of weekly semaglutide or tirzepatide is associated with significant weight loss.

The addition of semaglutide or tirzepatide led to a reduction in total daily insulin dose.
Increased Time In Target Range (TIR) was observed without a higher risk for hypoglycemia or Diabetic Ketoacidosis (DKA).
Adjunctive treatment with empagliflozin also resulted in improved TIR and reduced insulin requirements.
Empagliflozin treatment was associated with an increase in mean plasma ketone value, while DKA remained rare.
Longer-duration studies with larger participant groups are needed to confirm the long-term safety and efficacy of these treatments.

Simplified

Automated Insulin Delivery (AID) systems represent the most effective and safe treatment for the management of type 1 diabetes (T1D). Antidiabetic agents used for the treatment of type 2 diabetes, such as the Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists (RAs), the dual Glucose-dependent Insulinotropic Polypeptide and GLP-1 RA and the Sodium-Glucose co-Transporter 2 inhibitors are associated with clinically significant weight loss and cardioprotective effect. Given the increased prevalence of overweight, obesity, and cardiovascular risk in patients with T1D, the addition of these medications to AID treatment is of considerable clinical interest. In this review limited data from randomized controlled and observational trials show that in overweight and obese patients with T1D treated with AID, the addition of weekly semaglutide, or tirzepatide is associated with significant weight loss, reduction in total daily insulin dose and increase in Time In target Range (TIR) without increased risk for hypoglycemia and Diabetic Ketoacidosis (DKA). Similarly, adjunctive treatment with empagliflozin resulted in increased TIR without increase in hypoglycemia, reduction in insulin requirements, and increase in the mean plasma ketone value, although DKA remained rare. However, studies of longer duration with more participants are required to establish the long-term safety and efficacy of these interventions in patients with T1D treated with AID.

Full Text

Full text is available at the source.

View Full Text ↗

Additional Treatments for People with Type 1 Diabetes Using Automated Insulin Pumps

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief